经会阴穿刺活检可检出仅位于前列腺前部的临床显著癌
单中心回顾性分析508例经会阴前列腺穿刺患者,评估前列腺内癌灶分布。12.0%的患者临床显著前列腺癌(csPCa)仅见于前部穿刺标本;PSA 4.1-10.0 ng/mL者中为6.6%,PSA>10.0 ng/mL者中为8.2%。结论认为经会阴途径可诊断经直肠途径可能漏诊的前部csPCa。
要点
- 经会阴穿刺可检出仅位于前列腺前部的csPCa。
- 全队列12.0%的csPCa仅见于前部穿刺标本。
- PSA 4.1-10.0 ng/mL者前部孤立csPCa为6.6%,>10.0 ng/mL者为8.2%。
核心结论
- 经会阴前列腺穿刺能够诊断仅位于前部、经直肠途径可能漏诊的临床显著前列腺癌。
研究设计与样本
- 单中心回顾性研究,纳入2016年2月至2018年3月接受经会阴前列腺穿刺的508例患者,评估癌灶在腺体内的分布。
主要发现
- 全队列中12.0%的患者csPCa仅在前部穿刺标本中检出。
- PSA 4.1-10.0 ng/mL组中6.6%的患者前部穿刺 alone 检出csPCa。
- PSA>10.0 ng/mL组中8.2%的患者前部穿刺 alone 检出csPCa。
关键数值与推荐
- 临床显著前列腺癌定义为国际泌尿病理学会(ISUP)分级分组2-5级。
- 仅前部检出csPCa者与后部或侧部检出任何癌者进行比较。
临床怎么用
- 对拟行前列腺穿刺的患者,经会阴途径有助于检出前部孤立csPCa,减少经直肠途径的漏诊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the incidence of clinically significant prostate cancer (csPCa) detected exclusively in the anterior prostate using transperineal prostate biopsy. PATIENTS AND METHODS: Histopathology results of all patients who underwent transperineal prostate biopsy between February 2016 and March 2018 at a single institution were assessed for distribution of cancer within the prostate. Patients with cancer found exclusively in the anterior prostate were then compared to those with any cancer found in the posterior or lateral prostate with International Society of Urological Pathology Grade Group 2-5 cancers being considered csPCa. RESULTS: A total of 508 patients were included. Overall, 12.0% of the cohort had csPCa detected only in anterior biopsies. When stratified by prostate-specific antigen (PSA) level, 6.6% of men with a PSA level of 4.1-10.0 ng/mL and 8.2% of men with a PSA level of >10.0 ng/mL had csPCa detected in the anterior prostate alone. CONCLUSION: Transperineal biopsy has the ability to diagnose anteriorly located csPCa that would potentially have been missed by the transrectal approach.
引用
- Cowan T, Baker E, McCray G, et al. Detection of clinically significant cancer in the anterior prostate by transperineal biopsy. BJU Int. 2020. PMID: 32463977. doi:10.1111/bju.15124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。